ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves IND for ADG-106 Study
americanpharmaceuticalreview
July 11, 2018Adagene has received notification from the FDA to proceed on its Investigational New Drug (IND) application to study its lead product (ADG-106) in patients with advanced solid tumors and non-Hodgkin lymphoma.
Pharma Sources Insight January 2025
